Stay updated on INTRUST: Urelumab/Nivolumab Combo Clinical Trial
Sign up to get notified when there's something new on the INTRUST: Urelumab/Nivolumab Combo Clinical Trial page.

Latest updates to the INTRUST: Urelumab/Nivolumab Combo Clinical Trial page
- CheckyesterdayChange DetectedThe page has undergone significant changes with the removal of several key research articles and their corresponding errata, which may affect the credibility and comprehensiveness of the content related to immunogenic tumors and cancer treatments.SummaryDifference0.4%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a clinical study on intratumoral urelumab combined with nivolumab, including detailed inclusion and exclusion criteria for participants. The revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference12%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.4%
Stay in the know with updates to INTRUST: Urelumab/Nivolumab Combo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INTRUST: Urelumab/Nivolumab Combo Clinical Trial page.